Assignee
SQUIBB & SONS LLC
US·35 granted patents·21 pending applications·954 citations·filing 2007–2025
Top patents by PatentIndex Score
56 records- 0199US10441655B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2016·Granted Oct 15, 2019·25 cites·22 claims
- 0299US9580507B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2016·Granted Feb 28, 2017·129 cites·30 claims
- 0399US9492539B2Monoclonal antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·119 cites·65 claims
- 0499US9492540B2Methods for treating cancer using anti-PD-1 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Nov 15, 2016·139 cites·79 claims
- 0599US9387247B2Monoclonal antibodies to programmed death 1 (PD-1)SQUIBB & SONS LLC·Filed 2014·Granted Jul 12, 2016·124 cites·45 claims
- 0699US9358289B2Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodiesSQUIBB & SONS LLC·Filed 2014·Granted Jun 7, 2016·137 cites·49 claims
- 0799US9273135B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Mar 1, 2016·109 cites·30 claims
- 0898US11001630B2Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted May 11, 2021·10 cites·20 claims
- 0998US10988536B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2020·Granted Apr 27, 2021·10 cites·20 claims
- 1098US10344089B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2017·Granted Jul 9, 2019·25 cites·20 claims
- 1198US9580505B2Human monoclonal antibodies to programmed death ligand 1 (PD-L1)SQUIBB & SONS LLC·Filed 2015·Granted Feb 28, 2017·37 cites·41 claims
- 1297US11530267B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Dec 20, 2022·2 cites·21 claims
- 1397US11236165B2Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 1497US11236163B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 1597US11236164B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Feb 1, 2022·4 cites·21 claims
- 1696US11512130B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2021·Granted Nov 29, 2022·2 cites·22 claims
- 1796US10988535B2Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereofSQUIBB & SONS LLC·Filed 2019·Granted Apr 27, 2021·10 cites·20 claims
- 1893US9631025B2Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 antibodiesSQUIBB & SONS LLC·Filed 2015·Granted Apr 25, 2017·11 cites·12 claims
- 1992US2026028416A1Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodiesSQUIBB & SONS LLC·Filed 2025·Application pending·0 cites
- 2091US9296822B2Human monoclonal antibodies to O8ESQUIBB & SONS LLC·Filed 2013·Granted Mar 29, 2016·15 cites·26 claims
- 2191US9138475B2Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1 antibodiesSQUIBB & SONS LLC·Filed 2013·Granted Sep 22, 2015·12 cites·16 claims
- 2289US9580467B2Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereofSQUIBB & SONS LLC·Filed 2015·Granted Feb 28, 2017·5 cites·1 claims
- 2387US11072664B2Interferon receptor 1 antibodies and their usesSQUIBB & SONS LLC·Filed 2019·Granted Jul 27, 2021·3 cites·20 claims
- 2486US9499632B2Human antibodies that bind CD22 and uses thereofSQUIBB & SONS LLC·Filed 2013·Granted Nov 22, 2016·8 cites·42 claims
- 2586US2023322919A1Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses ThereofSQUIBB & SONS LLC·Filed 2022·Application pending·0 cites
- 2686US2023272079A1Monoclonal Antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2023·Application pending·0 cites
- 2785US11292814B2Cation exchange chromatography methodsSQUIBB & SONS LLC·Filed 2018·Granted Apr 5, 2022·2 cites·13 claims
- 2884US10448622B2Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmissionSQUIBB & SONS LLC·Filed 2016·Granted Oct 22, 2019·1 cites·10 claims
- 2983US10385133B2Interferon receptor 1 antibodies and their usesSQUIBB & SONS LLC·Filed 2016·Granted Aug 20, 2019·2 cites·16 claims
- 3082US2023061544A1Human monoclonal antibodies to programmed death ligand 1 (pd-l1)SQUIBB & SONS LLC·Filed 2022·Application pending·0 cites
- 3182US2022403046A1Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodiesSQUIBB & SONS LLC·Filed 2022·Application pending·0 cites
- 3280US9226974B2Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereofSQUIBB & SONS LLC·Filed 2014·Granted Jan 5, 2016·2 cites·8 claims
- 3380US2025154254A1Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereofSQUIBB & SONS LLC·Filed 2025·Application pending·0 cites
- 3479US2020138945A1Monoclonal Antibodies to Programmed Death 1 (PD-1)SQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 3577US2021395375A1Interferon receptor 1 antibodies and their usesSQUIBB & SONS LLC·Filed 2021·Application pending·0 cites
- 3676US12157757B2Cation exchange chromatography methodsSQUIBB & SONS LLC·Filed 2022·Granted Dec 3, 2024·0 cites·12 claims
- 3775US2020236915A1Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmissionSQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 3874US2021298277A1Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmissionSQUIBB & SONS LLC·Filed 2021·Application pending·0 cites
- 3974US2020231671A1Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereofSQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 4073US9994633B2IP-10 antibodies and their usesSQUIBB & SONS LLC·Filed 2014·Granted Jun 12, 2018·1 cites·4 claims
- 4173US9988453B2Human monoclonal antibodies to O8ESQUIBB & SONS LLC·Filed 2016·Granted Jun 5, 2018·1 cites·16 claims
- 4271US2019119384A1Human ctla-4 antibodies and their usesSQUIBB & SONS LLC·Filed 2018·Application pending·0 cites
- 4371US2020062848A1Human monoclonal antibodies to programmed death ligand 1 (pd-l1)SQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 4469US9217033B2Monoclonal antibodies against Glypican-3SQUIBB & SONS LLC·Filed 2014·Granted Dec 22, 2015·1 cites·9 claims
- 4568US2019315881A1Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodiesSQUIBB & SONS LLC·Filed 2019·Application pending·0 cites
- 4664US2017158767A1Human monoclonal antibodies to programmed death ligand 1 (pd-l1)SQUIBB & SONS LLC·Filed 2017·Application pending·0 cites
- 4763US2016257753A1Human ctla-4 antibodies and their usesSQUIBB & SONS LLC·Filed 2016·Application pending·0 cites
- 4862US2017369568A1Interferon alpha antibodies and their usesSQUIBB & SONS LLC·Filed 2017·Application pending·0 cites
- 4962US2017190785A1Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodiesSQUIBB & SONS LLC·Filed 2017·Application pending·0 cites
- 5059US11312777B2Human monoclonal antibodies that bind CXCR4 and uses thereofSQUIBB & SONS LLC·Filed 2018·Granted Apr 26, 2022·0 cites·24 claims
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SQUIBB & SONS LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →